Only the shareholders can sell CytoDyn, not the Board and not the future CEO. The Proxy Group is interested in developing the full value of the company. To do that, a competent CEO with credibility is required. While Pourhassan has shown "true grit" to this point, a different type of leader and face of the company is now needed.